Terms: = Lymphoma AND SMAD2, MADH2, 4087, ENSG00000175387, MGC34440, MGC22139, hMAD-2, MADR2, JV18-1, hSMAD2, JV18 AND Prognosis
2 results:
1. Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma.
Rej A; Paladhi A; Daripa S; Sarkar D; Bhattacharyya S; Mondal I; Hira SK
Int Immunopharmacol; 2023 Jan; 114():109521. PubMed ID: 36470118
[TBL] [Abstract] [Full Text] [Related]
2. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
Yokoyama M; Ichinoe M; Okina S; Sakurai Y; Nakada N; Yanagisawa N; Jiang SX; Numata Y; Umezawa A; Miyazaki K; Higashihara M; Murakumo Y
Int J Hematol; 2017 May; 105(5):614-622. PubMed ID: 28032275
[TBL] [Abstract] [Full Text] [Related]